Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
about
MLK3 Signaling in Cancer InvasionFrom human genome to cancer genome: the first decadeTargeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model.Somatic mutations associated with MRI-derived volumetric features in glioblastomaTargeting the adaptability of heterogeneous aneuploidsuPAR induces expression of transforming growth factor β and interleukin-4 in cancer cells to promote tumor-permissive conditioning of macrophages.Rheumatoid arthritis is associated with rs17337023 polymorphism and increased serum level of the EGFR proteinmMAPS: a flow-proteometric technique to analyze protein-protein interactions in individual signaling complexes.MiR-330-mediated regulation of SH3GL2 expression enhances malignant behaviors of glioblastoma stem cells by activating ERK and PI3K/AKT signaling pathwaysMicroenvironmental stiffness enhances glioma cell proliferation by stimulating epidermal growth factor receptor signaling.Dendritic cell immunotherapy versus bevacizumab plus irinotecan in recurrent malignant glioma patients: a survival gain analysis.Network analysis of gene essentiality in functional genomics experiments.Targeted Therapy for MAPK Alterations in Pediatric Gliomas.Tyrphostin AG 1296 induces glioblastoma cell apoptosis in vitro and in vivo.EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.A bivalent recombinant immunotoxin with high potency against tumors with EGFR and EGFRvIII expression.Design, synthesis, and evaluation of cisplatin-containing EGFR targeting bioconjugates as potential therapeutic agents for brain tumorsThe EGF Receptor Promotes the Malignant Potential of Glioma by Regulating Amino Acid Transport System xc(-)Anti-cancer Therapies in High Grade Gliomas.Experimental validation of 5 in-silico predicted glioma biomarkers.Major vault protein supports glioblastoma survival and migration by upregulating the EGFR/PI3K signalling axisThe G-protein coupled chemoattractant receptor FPR2 promotes malignant phenotype of human colon cancer cells.Reversion of the ErbB malignant phenotype and the DNA damage response.Epidermal growth factor receptor as a therapeutic target in glioblastoma.Therapeutic resistance in cancer: microRNA regulation of EGFR signaling networks.Prognostic and predictive biomarkers in adult and pediatric gliomas: toward personalized treatment.Notching on Cancer's Door: Notch Signaling in Brain Tumors.STAT3 Activation in Glioblastoma: Biochemical and Therapeutic Implications.A Kinase Inhibitor Targeted to mTORC1 Drives Regression in Glioblastoma.Glioma Subclassifications and Their Clinical Significance.Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma.Anti-EGFR Agents: Current Status, Forecasts and Future Directions.LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.Shikonin and its derivatives inhibit the epidermal growth factor receptor signaling and synergistically kill glioblastoma cells in combination with erlotinib.The effects of ponatinib, a multi-targeted tyrosine kinase inhibitor, against human U87 malignant glioblastoma cells.Genetic delivery of an immunoRNase by an oncolytic adenovirus enhances anticancer activity.Tumor-targeted nanotherapeutics: overcoming treatment barriers for glioblastoma.A comparative survey of functional footprints of EGFR pathway mutations in human cancers.Exploration of Involved Key Genes and Signaling Diversity in Brain Tumors.
P2860
Q26746892-448B7761-27C7-4075-A3F9-B2E213C4D68AQ26827640-B7429561-B418-4692-8A1A-AC655077FC77Q27316967-5B824142-B1FF-4922-8229-DD6E5F9F296EQ28607337-74305706-D2CA-4CDD-A6C8-7D2C30BE5AB0Q28649939-51C0A76D-28D3-4E75-AB3D-C6EE68B17D0BQ30365899-7F0F0FDE-BC33-475E-9A0E-58E24C8B5623Q33898265-09E1FAF1-99F1-4F78-BD19-B7E4A5F44AC1Q33998215-79C4D539-CD19-4AA1-AEA6-9C9A990E1457Q35149540-AC43DEF5-F11B-4B57-A09B-0E2454E7BEFCQ35202307-F0DD0D08-9B17-430E-AA46-3949284F81AFQ36201736-18B90052-D35C-423B-ADEB-2FA90178C6A2Q36232406-C4F53F01-8B8A-4643-8980-820F8C0D94E0Q36233325-63A63F4A-267D-456C-9ADA-67A7771FC39EQ36334429-EF4CADA1-8FF6-4CE5-93EB-C4BB8552E82DQ36355848-B0D6EE3D-7F62-4B21-8D0A-3968868049F3Q36821054-89FE9FE1-3423-4A0D-AA29-51470ED9C84FQ36843748-AD20EE54-DBAC-4D7D-8F12-D25DE8959C6EQ36907976-F7F8D60B-3D6D-4878-A3A0-50EFB3B4309AQ36917721-1F026BAD-0823-41B1-A847-68D5983AEAC0Q37290626-CC9A76E8-3B14-4475-8965-1A033F77698BQ37312711-FF1968F3-B24D-43C5-8D56-055F54B5AC00Q37420167-B6194AE0-84FC-4329-A134-BF695CBABA47Q37447912-FA1D0664-6B67-48BD-969C-29CF8A6EBEACQ38047648-51DB816B-20CB-4B2C-A068-853CF812D906Q38098098-B50DAC5C-B8BC-47AE-B09C-08550DA8D3F0Q38172182-C4AEC760-42DC-45CE-AE39-14A2159E69B2Q38203283-09B0B57E-8FB4-46AC-9343-6B37B2CBC44BQ38324552-12DF47A8-9489-4C83-9851-A8A545F72044Q38671957-9B688BFF-061A-4D17-8B73-202B9C9C3187Q38712296-90AB06EE-9E58-4F21-A925-F1857AD3E89EQ38747746-1F2858B4-B37F-455B-8998-7617C99B8620Q38752350-677508AF-9999-42A6-81B0-92BED45BC9FFQ38832105-4E816E2C-C1CD-416B-8226-5B6678D4994BQ38888905-18946124-0E8C-4AF1-AF3C-02CFDF2227ADQ38908815-C34CCCD9-69B3-4521-A1BC-A36FD3DD629FQ38941959-4A2654C3-8265-4406-BC64-5B5C958F47C7Q38949072-FCFC46FD-AC70-4CD7-A36D-F1E5AC4F7EAAQ38998571-EF18E7D0-95D0-4CAF-91C8-4CA7C16C4B21Q39069318-39C8D5A6-495C-40EA-93A9-DD6A52FAD86AQ39298204-098C247E-7BBF-4E2A-BCAF-5407A5542529
P2860
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
@ast
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
@en
type
label
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
@ast
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
@en
prefLabel
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
@ast
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance.
@en
P2860
P1476
Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance
@en
P2093
T E Taylor
W K Cavenee
P2860
P304
P356
10.2174/156800912799277557
P577
2012-03-01T00:00:00Z